|Dr. Cameron Durrant M.D., MBA||Chairman and Chief Exec. Officer||516.83k||N/A||57|
|Mr. David L. Tousley M.B.A., CPA||Interim Chief Financial Officer||333.79k||N/A||61|
|Mr. Morgan Lam||Chief Scientific Officer||427.5k||N/A||52|
|Mr. Edward Painter MBA||Head of Communications and Investor Relations||N/A||N/A||N/A|
|Mr. Patrick Crutcher||Head of Bus. Devel.||N/A||N/A||N/A|
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is based in Brisbane, California.
KaloBios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.